Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.

Date publication

juillet 2019

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier , Pr FEUGIER Pierre , Dr DORVAUX Véronique

Tous les auteurs :
Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31339826

Résumé

The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final PFS and overall survival (OS) results from the PRIMA study after 9 years of follow-up and provide a final overview of safety.

Référence

J. Clin. Oncol.. 2019 Jul 24;:JCO1901073